Wesley Carpentier

SUDEVCO is the practice of Wesley Carpentier, PhD — a biotech operator and advisor with twenty years across industrial enzymes, fermentation platforms, and specialty ingredients. The work spans sector research, strategic advisory, and dealmaking.

Background

I trained as a microbiologist at Ghent University, completing a PhD in biochemistry and microbiology before moving into business. The arc since has been about turning microbial science and fermentation into new and more sustainable products — and the durable companies behind them — across agriculture, food, health, feed, fuel, and industrial biotech.

Between 2005 and 2008 I co-authored the business plan and helped raise €21 million in public-private funding for the Bio Base Europe Pilot Plant, the open-access fermentation facility that today supports much of European bio-economy R&D.

I joined DuPont Industrial Biosciences (then Danisco / Genencor) in 2008 to learn the discipline of new- market development as DuPont practised it. Over four years I led a small international team mapping new applications for microbial enzymes and fermentation across Europe, North America, and China — opening commercial programmes in health ingredients, feed, food processing, and bio-chemicals that totalled around USD 100 million in pipeline value.

In 2012 I founded SUDEVCO as a venture-building and advisory practice. Since then I have advised more than twenty organisations — from SMEs and scale-ups to mid-sized and large corporates and investment funds — along two directions: due diligence and techno-economic assessment, and corporate strategy, turnaround, expansion and transformation. The work often carries a strong emphasis on business development, negotiation support, and alliance management, at the interface of IP, regulatory science, technology, scale-up, and internationalisation. One of the early engagements was preparing Taxon Biosciences — a microbial discovery platform targeting rare and low-abundance species — through value proposition, exit strategy, and competitive positioning, contributing to its trade sale to DuPont Pioneer.

From 2016 to 2024 I held two operator roles in parallel with the advisory work. At Inbiose I served as Chief Commercial Officer (2016–2020) and returned to lead the company in 2024. The CCO mandate was to grow Inbiose from a single human milk oligosaccharide (HMO) into an unusually broad portfolio of HMOs and other glycans — one shaped by what consumers and the market actually needed, rather than by what the science made easy. The team grew from fifteen to roughly fifty, and the licensing and co-development agreements I led with global ingredient and FMCG majors became a major source of partner funding — and helped attract over €15 million in growth equity.

At S-Biomedic (2020–2023) I served as Chief Commercial Officer, then Chief Operating Officer through the company's acquisition by Beiersdorf — converting an academic proof-of-concept into a market-ready live-bacteria platform, launching a direct-to- consumer brand for traction validation, and leading the post-deal integration.

What SUDEVCO does today

SUDEVCO is a bespoke, independent practice working across two lenses: Bioindustry & Bio-based Economy — industrial biotechnology, biorefining, animal nutrition, agtech, and bio-based chemicals; and Health & Nutrition — specialty bio-ingredients, biotics, and functional and medical nutrition. The work is operator-led, and it runs in three lines.

The first is sector research and intelligence — premium investor briefs and competitive landscapes with named forward calls, in sectors where the network and the operating experience produce insight that desk research cannot. The current catalogue covers human milk oligosaccharides; reports in industrial enzymes, precision fermentation and synthetic biology, the broader biotics-and-microbiome space, and classic global fermentation are in scoping. The thesis on each is specific and named; the work names the players, the cost economics, and a forward call.

The second is strategic advisory — sector diligence (including VC and PE pre-investment and distressed-asset diligence), market-entry and cross-border expansion across Europe, the US and Asia, regulatory roadmaps, partner identification and partnership financing, and cost-effective scale-up. It serves investors (VC and PE), corporates, founders taking a company to exit, technology-transfer offices, and family-owned and mid-market industrials. This work draws on the same sector intelligence as the research, applied to a specific decision.

The third is BD and dealmaking — licensing negotiation, partnership and joint-venture structuring, and M&A advice across buy-side, sell-side and MBO support, including special-situations work (restart and asset purchases from administration), for founders, corporate BD teams and restart investors. This is operator-and-negotiator work. Founders find that unexpectedly useful when they are sitting across the table from a corporate strategic for the first time.

Credentials